While targeted therapies such as tamoxifen and trastuzumab benefit patients with ER+ and HER2+ breast cancers [2, 3], the basal phenotype, characterized by the lack of expression of ERα, PR and HER2 (referred to as triple-negative breast cancer), is more difficult to treat and often has a poor prognosis. This evidence concerns the gene ESR1 and breast cancer.